Recent studies have revealed that ZDHHC17 promotes NLRP3 activation by palmitoylating the Cys419 residue, thereby facilitating the interaction between NLRP3 and NEK7, which drives the IBD progression. Here, NLRP3 is linked to inflammatory bowel disease.